AR049438A1 - Derivados con estructura aroil-o-piperidina, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus aplicaciones terapeuticas - Google Patents

Derivados con estructura aroil-o-piperidina, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus aplicaciones terapeuticas

Info

Publication number
AR049438A1
AR049438A1 ARP050102372A ARP050102372A AR049438A1 AR 049438 A1 AR049438 A1 AR 049438A1 AR P050102372 A ARP050102372 A AR P050102372A AR P050102372 A ARP050102372 A AR P050102372A AR 049438 A1 AR049438 A1 AR 049438A1
Authority
AR
Argentina
Prior art keywords
radical
alkyl
hydrogen atom
arylalkyl
alkynyl
Prior art date
Application number
ARP050102372A
Other languages
English (en)
Inventor
Marie Noelle Denuault
Stephane Yvon
Peter Kane
Julia A H Llainton
Avril A B Robertson
Bernd Wendt
Philippe Guedat
Francois Collonges
Oliver Chevreuil
Herve Dumas
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR049438A1 publication Critical patent/AR049438A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/08—Preparation by ring-closure
    • C07D213/09—Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles
    • C07D213/12—Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles from unsaturated compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a derivados de estructura aroil-O-piperidina de la formula general (1), en la que R1 está seleccionado de un átomo de hidrogeno, un radical alquilo y un radical alcoxi; R2 está seleccionado de un radical alquilo, un radical alcoxi, un radical trifluorometilo y un radical trifluorometoxi; R3 está seleccionado de un átomo de hidrogeno y un radical alquilo; R4 está seleccionado de un átomo de hidrogeno, un radical alquilo, un radical alquenilo, un radical alquinilo, un radical arilo, un radical arilalquilo, un radical arilalquenilo, un radical arilalquinilo, un radical cicloalquilo, un radical cicloalquilalquilo, un radical heterociclilo, un radical heterociclilalquilo, un radical heteroarilo, un radical heteroarilalquilo, un radical -C(=Z)-R5, en donde Z representa un átomo de azufre o de oxígeno, y un radical -S(O)n-R6, en donde n representa 1 o 2; R5 está seleccionado de un átomo de hidrogeno, un radical alquilo, un radical alquenilo, un radical alquinilo, un radical cicloalquilo, un radical cicloalquilalquilo, un radical heterocicloalquilo, un radical heterocicloalquilalquilo, un radical arilo, un radical arilalquilo, un radical heteroarilo, un radical heteroarilalquilo, un radical -O-R7, un radical -C(=O)-O-R7, un radical -S-R8 y un radical -NR9R10; R6 está seleccionado de un radical alquilo, un radical alquenilo, un radical alquinilo, un radical cicloalquilo, un radical heterocicloalquilo, un radical arilo, un radical heteroarilo, un radical cicloalquilalquilo, un radical heterocicloalquilalquilo, un radical arilalquilo y un radical heteroarilalquilo; R7 está seleccionado de un átomo de hidrogeno, un radical alquilo, un radical alquenilo, un radical alquinilo, un radical alcoxialquilo, un radical cicloalquilo, un radical heterocicloalquilo, un radical arilo, un radical heteroarilo, un radical cicloalquilalquilo, un radical heterocicloalquilalquilo, un radical arilalquilo y un radical heteroarilalquilo; R8 está seleccionado de un átomo de hidrogeno, un radical alquilo, un radical alquenilo y un radical alquinilo; R9 está seleccionado de un átomo de hidrogeno y un radical alquilo; R10 está seleccionado de un átomo de hidrogeno, un radical alquilo, opcionalmente sustituido con un radical -C(=O)-O-R7, un radical alquenilo, un radical alquinilo, un radical -S(O)n-R6, en donde n representa 1 o 2, un radical cicloalquilo, un radical heterocicloalquilo, un radical arilo, un radical heteroarilo, un radical cicloalquilalquilo, un radical heterocicloalquilalquilo, un radical arilalquilo y un radical heteroarilalquilo; sus posibles isomeros geométricos y/u opticos, epímeros y formas tautoméricas, y posibles formas oxidadas, especialmente oxidos de amina, los solvatos e hidratos de estos compuestos; y también sus posibles sales farmacéuticamente aceptables con un ácido o una base, o bien los profármacos farmacéuticamente aceptables de estos compuestos. Aplicacion de los compuestos de la formula (1) en el tratamiento de hipertrigliceridemias, hipercolesterolemias y dislipidemias, y en la prevencion o el tratamiento de la obesidad.
ARP050102372A 2004-06-11 2005-06-09 Derivados con estructura aroil-o-piperidina, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus aplicaciones terapeuticas AR049438A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0406345A FR2871463B1 (fr) 2004-06-11 2004-06-11 Derives a structure aroyl-o-piperidine, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en therapeutique

Publications (1)

Publication Number Publication Date
AR049438A1 true AR049438A1 (es) 2006-08-02

Family

ID=34946344

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102372A AR049438A1 (es) 2004-06-11 2005-06-09 Derivados con estructura aroil-o-piperidina, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus aplicaciones terapeuticas

Country Status (11)

Country Link
US (1) US7723358B2 (es)
EP (1) EP1753721B1 (es)
JP (1) JP4988573B2 (es)
AR (1) AR049438A1 (es)
AT (1) ATE438623T1 (es)
AU (1) AU2005251876B2 (es)
CA (1) CA2569883C (es)
DE (1) DE602005015841D1 (es)
ES (1) ES2330023T3 (es)
FR (1) FR2871463B1 (es)
WO (1) WO2005121091A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
EP2076487B1 (en) * 2006-10-24 2010-05-26 Janssen Pharmaceutica N.V. Mtp inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010043592A1 (en) * 2008-10-15 2010-04-22 Revotar Biopharmaceuticals Ag Lipase inhibitors for use for the treatment of obesity
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8785608B2 (en) 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013378D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
US20020032238A1 (en) * 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
DE10033337A1 (de) * 2000-07-08 2002-01-17 Boehringer Ingelheim Pharma Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US20040058903A1 (en) * 2000-10-05 2004-03-25 Hisashi Takasugi Benzamide compounds as apo b secretion inhibitors
JO2409B1 (en) * 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
FR2816940A1 (fr) * 2000-11-23 2002-05-24 Lipha Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation
GB0129015D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia

Also Published As

Publication number Publication date
EP1753721A1 (en) 2007-02-21
DE602005015841D1 (de) 2009-09-17
US20070254919A1 (en) 2007-11-01
JP4988573B2 (ja) 2012-08-01
EP1753721B1 (en) 2009-08-05
CA2569883C (en) 2013-03-05
CA2569883A1 (en) 2005-12-22
ES2330023T3 (es) 2009-12-03
FR2871463A1 (fr) 2005-12-16
AU2005251876A1 (en) 2005-12-22
ATE438623T1 (de) 2009-08-15
FR2871463B1 (fr) 2006-09-22
US7723358B2 (en) 2010-05-25
JP2008501739A (ja) 2008-01-24
WO2005121091A1 (en) 2005-12-22
AU2005251876B2 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
AR049438A1 (es) Derivados con estructura aroil-o-piperidina, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus aplicaciones terapeuticas
RU2502730C2 (ru) Сульфонамидные соединения и их применение
EA200600527A1 (ru) Активирующее ppar соединение и содержащая его фармацевтическая композиция
AR063101A1 (es) Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2.
AR063680A1 (es) Derivados de pirazolo[1, 5-a]pirimidina, metodos e intermediario para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion de mglur5.
AR044909A1 (es) Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia
DK1258484T3 (da) Nye isoxazol- og thiazolforbindelser og anvendelse deraf som lægemidler
AR061371A1 (es) Amino - imidazolonas y su uso como medicamento para la enfermedad de alzheimer y otras enfermedades neurodegenerativas.
PE20081531A1 (es) Nuevos compuestos 620
RS53061B (en) INHIBITORI PROTEIN KINAZE
CO5540309A2 (es) Derivados de 4-(fenil-piperazinil-metil) benzamida y sus usos para el tratamiento del dolor, la ansiedad o desordenes gastrointestinales
AR061642A1 (es) Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas
EA201170096A1 (ru) Замещенные производные пиримидона
AR048289A1 (es) Eteres de anillos imidazo sulfona sustituidos.
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
AR061994A1 (es) Uso de derivados de imidazol activadores de ampk, su proceso de preparacion y composiciones farmaceuticas que los comprenden
RS52546B (en) 1H-BENZIMIDAZOL-4-CARBOXAMIDES SUBSTITUTED WITH QUATERNERN CARBON AT POSITION-2 ARE POWERFUL PARP INHIBITORS
AR036659A1 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
AR061370A1 (es) Derivados de imidazopirimidina
NO20061126L (no) Aminopyroner og deres anvendelse som ATM-inhibitorer
CO6190582A2 (es) Derivados de heteroarilamida
ATE420859T1 (de) Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren
AR070263A1 (es) Derivados de oxazepinopirimidinona arilamido sustituidos, utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, medicamentos que los contienen y proceso de preparacion e intermediarios.
HUP0300920A1 (hu) Szubsztituált benzidszármazékok és gyógyszerként történő felhasználásuk

Legal Events

Date Code Title Description
FB Suspension of granting procedure